# EDGAR Filing Document

**Accession Number:** 0001953926
**File Stem:** 0001193125-25-238370
**Filing Date:** 2025-10
**Character Count:** 24971
**Document Hash:** bc71acc99253b35a52818054c701b130
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-238370.hdr.sgml**: 20251014

**ACCESSION NUMBER**: 0001193125-25-238370

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251014

**DATE AS OF CHANGE**: 20251014

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zenas BioPharma, Inc.
- **CENTRAL INDEX KEY:** 0001953926
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94625
- **FILM NUMBER:** 251390080

**BUSINESS ADDRESS:**
- **STREET 1:** 852 WINTER STREET, SUITE 250
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 857-271-2954

**MAIL ADDRESS:**
- **STREET 1:** 852 WINTER STREET, SUITE 250
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zenas BioPharma (Cayman) Ltd
- **DATE OF NAME CHANGE:** 20221108
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Longitude Capital Partners IV, LLC
- **CENTRAL INDEX KEY:** 0001829169

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 2740 SAND HILL ROAD
- **STREET 2:** 2ND FLOOR
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 650-854-5700

**MAIL ADDRESS:**
- **STREET 1:** 2740 SAND HILL ROAD
- **STREET 2:** 2ND FLOOR
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**ZENAS BIOPHARMA, INC.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**98937L105**

*(CUSIP Number)*

**Patrick G. Enright,**<br>Longitude Capital Partners IV, LLC<br>2740 Sand Hill Road, 2nd Floor<br>Menlo Park CA 94025<br>(650) 854-5700

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/09/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **98937L105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Longitude Capital Partners IV, LLC** | Name of reporting person<br>**Longitude Capital Partners IV, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1832669.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1832669.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1832669.00** | Aggregate amount beneficially owned by each reporting person<br>**1832669.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.4%** | Percent of class represented by amount in Row (11)<br>**3.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** All shares are held of record by LVPIV (as defined in Item 2(a) below). LCPIV (as defined in Item 2(a) below) is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these securities.

Based on 53,421,343 shares outstanding, consisting of (A) 42,110,313 shares of Common Stock outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as filed with the Securities and Exchange Commission (the "Commission") on August 12, 2025 (the "Form 10-Q"), plus (B) 5,000,000 shares of common stock issued by the Issuer to InnoCare Pharma Inc. on October 7, 2025, plus (C) 6,311,030 shares of common stock issued by the Issuer to certain investors pursuant to that certain Securities Purchase Agreement, dated as of October 7, 2025, in the case of (B) and (C), each as reported by the Issuer in its Registration Statement on Form S-3ASR filed with the Commission on October 8, 2025 (the "Form S-3").

| **CUSIP No.** | **98937L105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Longitude Venture Partners IV, L.P.** | Name of reporting person<br>**Longitude Venture Partners IV, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1832669.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1832669.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1832669.00** | Aggregate amount beneficially owned by each reporting person<br>**1832669.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.4%** | Percent of class represented by amount in Row (11)<br>**3.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** All shares are held of record by LVPIV. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of LCPIV and may each be deemed to share voting, investment and dispositive power with respect to these securities.

Based on 53,421,343 shares outstanding, consisting of (A) 42,110,313 shares of Common Stock outstanding, as reported in the Form 10-Q, plus (B) 5,000,000 shares of common stock issued by the Issuer to InnoCare Pharma Inc. on October 7, 2025, plus (C) 6,311,030 shares of common stock issued by the Issuer to certain investors pursuant to that certain Securities Purchase Agreement, dated as of October 7, 2025, in the case of (B) and (C), each as reported in the Form S-3.

| **CUSIP No.** | **98937L105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Longitude Prime Partners, LLC** | Name of reporting person<br>**Longitude Prime Partners, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**774530.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**774530.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**774530.00** | Aggregate amount beneficially owned by each reporting person<br>**774530.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.4%** | Percent of class represented by amount in Row (11)<br>**1.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** All shares are held of record by LPF (as defined in Item 2(a) below). LPP (as defined in Item 2(a) below) is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

Based on 53,421,343 shares outstanding, consisting of (A) 42,110,313 shares of Common Stock outstanding, as reported in the Form 10-Q, plus (B) 5,000,000 shares of common stock issued by the Issuer to InnoCare Pharma Inc. on October 7, 2025, plus (C) 6,311,030 shares of common stock issued by the Issuer to certain investors pursuant to that certain Securities Purchase Agreement, dated as of October 7, 2025, in the case of (B) and (C), each as reported in the Form S-3.

| **CUSIP No.** | **98937L105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Longitude Prime Fund, L.P.** | Name of reporting person<br>**Longitude Prime Fund, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**774530.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**774530.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**774530.00** | Aggregate amount beneficially owned by each reporting person<br>**774530.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.4%** | Percent of class represented by amount in Row (11)<br>**1.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** All shares are held of record by LPF. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

Based on 53,421,343 shares outstanding, consisting of (A) 42,110,313 shares of Common Stock outstanding, as reported in the Form 10-Q, plus (B) 5,000,000 shares of common stock issued by the Issuer to InnoCare Pharma Inc. on October 7, 2025, plus (C) 6,311,030 shares of common stock issued by the Issuer to certain investors pursuant to that certain Securities Purchase Agreement, dated as of October 7, 2025, in the case of (B) and (C), each as reported in the Form S-3.

| **CUSIP No.** | **98937L105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Patrick G. Enright** | Name of reporting person<br>**Patrick G. Enright** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**24323.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2607199.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**24323.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2607199.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2631522.00** | Aggregate amount beneficially owned by each reporting person<br>**2631522.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.9%** | Percent of class represented by amount in Row (11)<br>**4.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Consists of (A) 11,990 shares held by Mr. Enright, and (B) 12,333 shares underlying options held by Mr. Enright, which are exercisable within 60 days of this Statement.

Consists of (A) 1,832,669 shares held of record by LVPIV, and (B) 774,530 shares held of record by LPF. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to the shares held of record by LVPIV. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the shares held by LPF. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVPIV and LPF.

Based on 53,433,676 shares outstanding, consisting of (A) 42,110,313 shares of Common Stock outstanding, as reported in the Form 10-Q, plus (B) 5,000,000 shares of common stock issued by the Issuer to InnoCare Pharma Inc. on October 7, 2025, plus (C) 6,311,030 shares of common stock issued by the Issuer to certain investors pursuant to that certain Securities Purchase Agreement, dated as of October 7, 2025, in the case of (B) and (C), each as reported in the Form S-3, plus (D) 12,333 shares underlying options held by Mr. Enright, which are exercisable within 60 days of this Statement.

| **CUSIP No.** | **98937L105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Juliet Tammenoms Bakker** | Name of reporting person<br>**Juliet Tammenoms Bakker** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2607199.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2607199.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2607199.00** | Aggregate amount beneficially owned by each reporting person<br>**2607199.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.9%** | Percent of class represented by amount in Row (11)<br>**4.9%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Consists of (i) 1,832,669 shares held of record by LVPIV and (ii) 774,530 shares held of record by LPF. LCPIV is the general partner of LVPIV and may be deemed to have voting, investment and dispositive power with respect to the shares held of record by LVPIV. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the shares held by LPF. Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of LCPIV and LPP and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVPIV and LPF.

Based on 53,421,343 shares outstanding, consisting of (A) 42,110,313 shares of Common Stock outstanding, as reported in the Form 10-Q, plus (B) 5,000,000 shares of common stock issued by the Issuer to InnoCare Pharma Inc. on October 7, 2025, plus (C) 6,311,030 shares of common stock issued by the Issuer to certain investors pursuant to that certain Securities Purchase Agreement, dated as of October 7, 2025, in the case of (B) and (C), each as reported in the Form S-3.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
ZENAS BIOPHARMA, INC.

**(c) Address of Issuer's Principal Executive Offices:**
852 Winter Street, Suite 250, Waltham, MA, 02451

**Item 4. Purpose of Transaction**

The information set forth in Item 4 of the Original Schedule 13D is incorporated herein by reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See Items 7-11 of the cover pages of this Statement and Item 2 above.

**(b)**
See Items 7-11 of the cover pages of this Statement and Item 2 above.

**(c)**
Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Items 3 and 4 of this Statement is incorporated herein by reference.

In connection with the PIPE, on October 7, 2025, the Issuer entered into a Registration Rights Agreement (the "PIPE Registration Rights Agreement") with the PIPE Investors, pursuant to which the Issuer filed the Form S-3 to register the PIPE Shares for resale. The Issuer granted the PIPE Investors customary indemnification rights in connection with the PIPE Registration Rights Agreement. The PIPE Investors have also granted the Issuer customary indemnification rights in connection with the PIPE Registration Rights Agreement.

The above summary of the PIPE Registration Rights Agreement is qualified by reference to such description and the full text of the PIPE Registration Rights Agreement, a form of which is filed as Exhibit 2 to this Amendment and is incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Longitude Capital Partners IV, LLC

**Signature:** /s/ Cristiana Blauth Oliveira

**Name/Title:** Cristiana Blauth Oliveira, Authorized Signatory

**Date:** 10/14/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Longitude Venture Partners IV, L.P.

**Signature:** By Longitude Capital Partners IV, LLC, General Partner, /s/ Cristiana Blauth Oliveira

**Name/Title:** Cristiana Blauth Oliveira, Authorized Signatory

**Date:** 10/14/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Longitude Prime Partners, LLC

**Signature:** /s/ Cristiana Blauth Oliveira

**Name/Title:** Cristiana Blauth Oliveira, Authorized Signatory

**Date:** 10/14/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Longitude Prime Fund, L.P.

**Signature:** By Longitude Prime Partners, LLC, General Partner, /s/ Cristiana Blauth Oliveira

**Name/Title:** Cristiana Blauth Oliveira, Authorized Signatory

**Date:** 10/14/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Patrick G. Enright

**Signature:** /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright

**Name/Title:** Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright

**Date:** 10/14/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Juliet Tammenoms Bakker

**Signature:** /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker

**Name/Title:** Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker

**Date:** 10/14/2025